This article is over a month old and may contain outdated advice from the authorities regarding coronary heart disease.
Stay up to date in NRK’s overview, or through FHIs nettsider.
–
It emerged at a press conference Monday morning.
– We do not recommend that these vaccines be used in the national vaccination program. We give advice on using the vaccines voluntarily, but the committee split up, says the committee’s leader Lars Vorland.
At the same time, the National Institute of Public Health announced that they recommend that the Janssen vaccine not be used in the active coronary vaccination program as the situation is now.
It writes FHI on their websites.
– Our goal is to protect as many people as possible, as quickly as possible, to reopen society and get everyday life back. It is therefore a difficult decision to recommend that one of the coronary vaccines not be used actively in the program. Nevertheless, we believe that this is the right decision as the infection situation in Norway is now, says infection control director Geir Bukholm at the National Institute of Public Health.
Professor of molecular immunology Anne Spurkland, says there are difficult assessments to be made.
– The vaccines protect against covid-19, but at the same time the AstraZeneca vaccine has been linked to very serious side effects, especially in Norway where we have actually lost four people who received the vaccine, says Spurkland.
Professor of Molecular Immunology Anne Spurkland
–
A total of around 135,000 AstraZeneca doses were administered in Norway before the use of the vaccine was suspended.
– No country in the world has had several blood clot cases per. dose than Norway, according to Spurkland.
She says there are several difficult considerations the committee has faced.
– We vaccinate to get society started. There are major financial consequences to having it postponed, so they probably take that into account. In addition, there are international consequences. That is, what signals we send to other countries, says the professor.
The government decides
The committee has been commissioned to look at the consequences of using or not using the vaccines from AstraZeneca and Janssen (Johnson & Johnson) in the vaccination program.
The report will be presented to Minister of Health Bent Høie (H) at a press conference at 10 am on Monday morning. The government will then decide whether the vaccines will be used in Norway.
The use of the vaccines has been temporarily suspended due to a number of blood clot cases associated with the vaccines.
In April, the NIPH recommended that the government to drop the two vaccines, but the government wanted a broader assessment.
–
